MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ramatroban

CAS No. : 116649-85-5

MCE 站：Ramatroban

产品活性：Ramatroban 是一种选择性血栓素 A2 (TxA₂，IC₅₀=14 nM) 拮抗剂。Ramatroban 还通过抑制 PGD₂ 结合从而拮抗 CRTH2 (IC₅₀=113 nM)。

研究领域：GPCR/G Protein

作用靶点：Prostaglandin Receptor

In Vitro: Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC₅₀ of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D₂ receptor DP2 (CRTH2) with an IC₅₀ of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC₅₀ of 15 μM. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD₂-stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2, and surprisingly, these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2, and inhibits PGD₂-induced migration of eosinophils via CRTH2 blockade. ³H-labeled PGD₂ binds to a single site on CRTH2 transfectants with high affinity (K_D=6.3 nM, B_max=450 pM). Nonlabeled PGD₂ inhibits the binding of ³H-labeled PGD₂ to CRTH2 transfectants in a concentration-dependent manner with an EC₅₀ value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of ³H-labeled PGD₂ to CRTH2, albeit with much lower potency (IC₅₀=100 nM). Ramatroban also inhibits PGD₂-induced Ca²⁺ mobilization in CRTH2 transfectants to almost the same extent with an IC₅₀ value of 30 nM. Ramatroban completely inhibits the PGD₂-induced migration of eosinophils in a concentration-dependent manner with an IC₅₀ value of 170 nM.

In Vivo: Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2^+/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p<0.01). In addition, tumor-impaired social interaction and object exploratory behavior in CRTH2^+/+ mice are completely reversed by a single injection of Ramatroban, even when the tumor is enlarged.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Prostaglandin E2  |  Prostaglandin E1  |  Iloprost  |  PF-04418948  |  Tranilast  |  ONO-AE3-208  |  AH 6809  |  U-46619  |  Latanoprost  |  Laropiprant  |  Rebamipide  |  Travoprost  |  RO1138452  |  p-Hydroxycinnamic acid  |  Bimatoprost  |  Pectolinarin  |  Taprenepag  |  Dinoprost tromethamine salt  |  (+)-Cloprostenol  |  Dazoxiben  |  Evatanepag  |  L-798106  |  Seratrodast  |  Nedocromil  |  Treprostinil  |  CAY10471 Racemate  |  Cloprostenol sodium salt  |  L 888607  |  AZ12672857  |  Prostaglandin D2

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。